| A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Nature and Objective
This Phase 1, first-in-human study investigates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of actinium-225-macropa-pelgifatamab (BAY3546828) in individuals with advanced metastatic castration-resistant prostate cancer (mCRPC). The radioligand therapy targets prostate-specific membrane antigen (PSMA) and delivers alpha radiation directly to cancer cells. The trial aims to identify an optimal dose that balances safety with therapeutic efficacy
Stade de la Maladie: Avancé ou métastatique
Organe: Prostate
Maladie: mCRPC